Literature DB >> 17899372

Colocalisation of predicted exonic splicing enhancers in BRCA2 with reported sequence variants.

Christopher A Pettigrew1, Nicola Wayte, Ania Wronski, Paul K Lovelock, Amanda B Spurdle, Melissa A Brown.   

Abstract

Disruption of the breast cancer susceptibility gene BRCA2 is associated with increased risk of developing breast and ovarian cancer. Over 1800 sequence changes in BRCA2 have been reported, although for many the pathogenicity is unclear. Classifying these changes remains a challenge, as they may disrupt regulatory sequences as well as the primary protein coding sequence. Sequence changes located in the splice site consensus sequences often disrupt splicing, however sequence changes located within exons are also able to alter splicing patterns. Unfortunately, the presence of these exonic splicing enhancers (ESEs) and the functional effect of variants within ESEs it is currently difficult to predict. We have previously developed a method of predicting which sequence changes within exons are likely to affect splicing, using BRCA1 as an example. In this paper, we have predicted ESEs in BRCA2 using the web-based tool ESEfinder and incorporated the same series of filters (increased threshold, 125 nt limit and evolutionary conservation of the motif) in order to identify predicted ESEs that are more likely to be functional. Initially 1114 ESEs were predicted for BRCA2, however after all the filters were included, this figure was reduced to 31, 3% of the original number of predicted ESEs. Reported unclassified sequence variants in BRCA2 were found to colocalise to 55% (17/31) of these conserved ESEs, while polymorphisms colocalised to 0 of the conserved ESEs. In summary, we have identified a subset of unclassified sequence variants in BRCA2 that may adversely affect splicing and thereby contribute to BRCA2 disruption.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17899372     DOI: 10.1007/s10549-007-9714-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.

Authors:  Kajal Biswas; Ranabir Das; Julie M Eggington; Huanyu Qiao; Susan L North; Stacey Stauffer; Sandra S Burkett; Betty K Martin; Eileen Southon; Scott C Sizemore; Dmitry Pruss; Karla R Bowles; Benjamin B Roa; Neil Hunter; Lino Tessarollo; Richard J Wenstrup; R Andrew Byrd; Shyam K Sharan
Journal:  Hum Mol Genet       Date:  2012-06-07       Impact factor: 6.150

2.  Prediction and assessment of splicing alterations: implications for clinical testing.

Authors:  Amanda B Spurdle; Fergus J Couch; Frans B L Hogervorst; Paolo Radice; Olga M Sinilnikova
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

3.  Effect of BRCA2 sequence variants predicted to disrupt exonic splice enhancers on BRCA2 transcripts.

Authors:  Phillip J Whiley; Christopher A Pettigrew; Brooke L Brewster; Logan C Walker; Amanda B Spurdle; Melissa A Brown
Journal:  BMC Med Genet       Date:  2010-05-28       Impact factor: 2.103

4.  Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction.

Authors:  Barbara Wappenschmidt; Alexandra A Becker; Jan Hauke; Ute Weber; Stefanie Engert; Juliane Köhler; Karin Kast; Norbert Arnold; Kerstin Rhiem; Eric Hahnen; Alfons Meindl; Rita K Schmutzler
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

5.  Identification of Eight Spliceogenic Variants in BRCA2 Exon 16 by Minigene Assays.

Authors:  Eugenia Fraile-Bethencourt; Alberto Valenzuela-Palomo; Beatriz Díez-Gómez; Alberto Acedo; Eladio A Velasco
Journal:  Front Genet       Date:  2018-05-24       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.